Global ETD Search

61	Elektrochemická impedanční spektroskopie jako charakterizační metoda modifikovaných nanostrukturovaných elektrod / Electrochemical impedance spectroscopy as a nanostructured bioelectrodes characterization method Vrbová, Eva January 2015 (has links) Diploma thesis deals of nanostructured surfaces, nanoparticles and electrochemical characterization methods such as cyclic voltammetry, differential pulse voltammetry and electrochemical impedance spectroscopy. The aim of this thesis is a theoretical research issues of production and characterization nanostructured modified electrodes. The practical part is the production of biomodified nanostructured electrodes by anodi- zation W/Al layers with galvanic deposition of gold or deposition of mercury, a modifi- cation of the electrodes by 11-mercaptoundecanoic acid and by bovine serum albumin (BSA). The thesis includes SEM images of nanostructured electrodes contact angle mea- surements of these electrodes and form an electrical circuit with subsequent simulation waveforms.
62	Bovint serum albumin påverkar överlevnad och Aβ-nivåer i Alzheimers sjuka Drosophila flugor. : Bovine serum albumin affects survival and Aβ-levels in Alzheimer's diseased Drosophila flies. Tani, Milena January 2024 (has links) Alzheimer's disease (AD) was first described more than 100 years ago and is today the most common cause of dementia. It is one of the progressive neurodegenerative diseases that affect 47 million people around the world between the ages of 60 and 90. One of the contributing factors to AD is extracellular amyloid – β (Aβ) plaques that form as a result of protein aggregation. These Aβ proteins are neurotoxic, leading to degeneration of brain neurons and loss of cognitive abilities. Because AD largely affects society, researchers are constantly working to find a cure, which currently does not exist. The purpose of this study was to use Drosophila melanogaster as a living organism model for the expression of two types of Aβ proteins related to AD, Arctic (Glu22Gly) and TandemAβ, and to study the survival of these AD flies when Bovine serum albumin (BSA) was added to the fly food. The hypothesis was that BSA would be effective in slowing down and/or preventing formation of toxic Aβ-aggregates. The focus was therefore to investigate whether the AD flies would live longer if they were allowed to eat Bovine serum albumin and whether the soluble/insoluble Aβ levels in these flies would decrease in comparison to the control AD flies that were not allowed to eat BSA. The effect of BSA on toxicity was evaluated using survival assay on male flies and the levels of soluble/insoluble Aβ were evaluated using Meso Scale Discovery (MSD) on female flies. In both experiments, the following six groups of flies were examined: myow1118 ± BSA; myoArctic ± BSA; myoTandemAβ ± BSA. Conclusions from the studies are that the survival of AD flies could not be extended by adding 0.61 mM BSA to the food, rather the data showed a weak but significant toxic effect in the presence of BSA in the AD flies. However, MSD data showed a reduction of insoluble Aβ aggregates and an equilibrium shift from insoluble Aβ aggregates to soluble Aβ aggregates in the presence of BSA in the AD flies. Equilibrium shifts were particularly detectable in Myo-TandemAβ flies fed with BSA. In Myo-Arctic flies fed with BSA only reduction of insoluble Aβ could be detected. This shows that it is not the amount of Aβ aggregates that is decisive for toxicity, but rather the presence of specific aggregates that have toxic properties. If BSA shows good results in further studies, it could be used in the future to improve AD symptoms in patients. Drosophila melanogaster Alzheimer AD BSA Bovine serum albumin Human serum albumin HSA Toxicity Aβ survival assay MSD Meso Scale Discovery Arctic (Glu22Gly) TandemAβ oligomers fibrills GAL4-UAS TM6B CyO enterocytes Drosophila melanogaster bananfluga Alzheimers BSA Bovint serum albumin Aβ Amyloida plack Överlevnad MSD Meso Scale Discovery AD Toxicitet Arctic (Glu22Gly) TandemAβ HSA Humant serum albumin GAL4-UAS TM6B CyO fibriller oligomerer enterocyter Natural Sciences Naturvetenskap Other Chemistry Topics Annan kemi Biochemistry and Molecular Biology Biokemi och molekylärbiologi Other Biological Topics Annan biologi Genetics Genetik
63	Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold Grant, David William 31 December 2010 (has links) Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics. Drug delivery Bone Bone morphogenic protein BMP BMP-2 rhBMP-2 bone graft tissue engineering scaffold bone tissue engineering regenerative medicine osteoinduction osteoconduction osteogenesis generative surgery autoraft replacement synthetic autograft replacement morphogenic bioactivity assay protein release kinetics bovine serum albumin model protein biomaterials biomaterial surface analysis scanning electron microscope application accelerating voltage application burst release sustained kinetics sustained delivery composite scaffold three phase scaffold PLGA calcium phosphate mineral-polymer composite sterilization BMP sterilization long-term storage BMP storage 0541
64	Reduced Burst Release of Bioactive rhBMP-2 from a Three-phase Composite Scaffold Grant, David William 31 December 2010 (has links) Recombinant human bone morphogenic proteins (rhBMPs) are extensively studied and employed clinically for treatment of various bone defects. Current clinical delivery vehicles suffer wasteful burst releases that mandate supra-physiological dosing driving concerns over safety and cost. It was therefore investigated whether a unique drug delivery vehicle sequestered within a composite scaffold could lower the burst release of rhBMP-2. PLGA-calcium phosphate tri-phasic composite scaffolds delivered model protein BSA with burst release of ~13% and sustained kinetics of 0.5-1.5% BSA/day up to 45 days. rhBMP-2 was delivered with zero burst release however at much lower levels, totaling 0.09% to 0.9 % release over 10 days, but had up to 6.3-fold greater bioactivity than fresh rhBMP-2 (p<0.05). In conclusion, the three-phase composite scaffold can deliver bioactive proteins with a reduced burst release and sustained secondary kinetics. Drug delivery Bone Bone morphogenic protein BMP BMP-2 rhBMP-2 bone graft tissue engineering scaffold bone tissue engineering regenerative medicine osteoinduction osteoconduction osteogenesis generative surgery autoraft replacement synthetic autograft replacement morphogenic bioactivity assay protein release kinetics bovine serum albumin model protein biomaterials biomaterial surface analysis scanning electron microscope application accelerating voltage application burst release sustained kinetics sustained delivery composite scaffold three phase scaffold PLGA calcium phosphate mineral-polymer composite sterilization BMP sterilization long-term storage BMP storage 0541

Page generated in 0.1769 seconds